This website, and electronic documents therein contains forward‐looking statements and other information that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Arch Biopartners Inc. (“Company”). There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward‐looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward‐looking statements should circumstances or management’s estimates or opinions change; however, these risks may be detailed from time to time in the Company’s public disclosures.
Prospective purchasers are responsible for their own due diligence regarding any investment in the Company.
Address: 545 King Street West Toronto, Ontario M5V 1M1 Canada
Mailing Address: 27 St. Clair Avenue East P.O. Box 305 Toronto, Ontario M4T 2M5 Canada
Arch Biopartners Inc. is focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. Arch works closely with the scientific community, universities and research institutions to advance and build the value of select preclinical technologies, develop the most promising intellectual property, and create value for its investors.
Arch has established a diverse portfolio that includes:
MetablokTM, a potential treatment for inflammation, sepsis and cancer metastasis;
AB569, a potential new treatment for antibiotic resistant bacterial infections;
‘Borg’ peptide coatings that increase corrosion resistance and decrease biofilm on various medical grade metals and plastics; and,
MetaMxTM, which targets elusive brain tumor initiating cells.